7 research outputs found
B-type natriuretic peptide: powerful predictor of endstage chronic heart failure in individuals with systolic dysfunction of the systemic right ventricle
Aim To assess whether B-type natriuretic peptide (BNP)
can serve as a predictor of end-stage chronic heart failure
(CHF) in patients with severe systolic dysfunction of the
systemic right ventricle (SRV).
Methods We performed a retrospective analysis in 28 patients
with severe systolic dysfunction of the SRV (ejection
fraction 23 ± 6%) who were evaluated as heart transplant
(HTx) candidates between May 2007 and October 2014.
The primary endpoints of the study (end-stage CHF) were
progressive CHF, urgent HTx, and ventricular assist device
(VAD) implantation. Plasma BNP levels were measured using
a chemiluminescent immunoassay.
Results During median follow-up of 29 months (interquartile
range, 9-50), 3 patients died of progressive CHF, 5
patients required an urgent HTx, and 6 patients underwent
VAD implantation. BNP was a strong predictor of end-stage
CHF (hazard ratio per 100 ng/L: 1.079, 95% confidence interval,
1.042-1.117, P<0.001). The following variables with
corresponding areas under the curve (AUC) were identified
as the most significant predictors of end-stage CHF:
BNP (AUC 1.00), New York Heart Association functional
class class III or IV (AUC 0.98), decompensated CHF in the
last year (AUC 0.96), and systolic dysfunction of the subpulmonal
ventricle (AUC 0.96).
Conclusion BNP is a powerful predictor of end-stage CHF
in individuals with systolic dysfunction of the SRV
Peritoneal dialysis induces alterations in the transcriptome of peritoneal cells before detectible peritoneal functional changes
Long-term peritoneal dialysis (PD) is associated with functional and structural alterations of the peritoneal membrane. Inflammation may be the key moment, and, consequently, fibrosis may be the end result of chronic inflammatory reaction. The objective of the present study was to identify genes involved in peritoneal alterations during PD by comparing the transcriptome of peritoneal cells in patients with short- and long-term PD. Peritoneal effluent of the long dwell of patients with stable PD was centrifuged to obtain peritoneal cells. The gene expression profiles of peritoneal cells using microarray between patients with short- and long-term PD were compared. Based on microarray analysis, 31 genes for quantitative RT-PCR validation were chosen. A 4-h peritoneal equilibration test was performed on the day after the long dwell. Transport parameters and protein appearance rates were assessed. Genes involved in the immune system process, immune response, cell activation, and leukocyte and lymphocyte activation were found to be substantially upregulated in the long-term group. Quantitative RT-PCR validation showed higher expression of CD24, lymphocyte antigen 9 (LY9), TNF factor receptor superfamily member 4 (TNFRSF4), Ig associated-α (CD79A), chemokine (C-C motif) receptor 7 (CCR7), carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), and IL-2 receptor-α (IL2RA) in patients with long-term PD, with CD24 having the best discrimination ability between short- and long-term treatment. A relationship between CD24 expression and genes for collagen and matrix formation was shown. Activation of CD24 provoked by pseudohypoxia due to extremely high glucose concentrations in dialysis solutions might play the key role in the development of peritoneal membrane alterations
The relationship between estimated GFR based on the CKD-EPI formula and renal inulin clearance in potential kidney donors
detail, Christ's hea
Recommended from our members
Accuracy and Feasibility of Real-time Continuous Glucose Monitoring in Critically Ill Patients After Abdominal Surgery and Solid Organ Transplantation.
OBJECTIVE: Glycemia management in critical care is posing a challenge in frequent measuring and adequate insulin dose adjustment. In recent years, continuous glucose measurement has gained accuracy and reliability in outpatient and inpatient settings. The aim of this study was to assess the feasibility and accuracy of real-time continuous glucose monitoring (CGM) in ICU patients after major abdominal surgery. RESEARCH DESIGN AND METHODS: We included patients undergoing pancreatic surgery and solid organ transplantation (liver, pancreas, islets of Langerhans, kidney) requiring an ICU stay after surgery. We used a Dexcom G6 sensor, placed in the infraclavicular region, for real-time CGM. Arterial blood glucose measured by the amperometric principle (ABL 800; Radiometer, Copenhagen, Denmark) served as a reference value and for calibration. Blood glucose was also routinely monitored by a StatStrip bedside glucose meter. Sensor accuracy was assessed by mean absolute relative difference (MARD), bias, modified Bland-Altman plot, and surveillance error grid for paired samples of glucose values from CGM and acid-base analyzer (ABL). RESULTS: We analyzed data from 61 patients and obtained 1,546 paired glucose values from CGM and ABL. Active sensor use was 95.1%. MARD was 9.4%, relative bias was 1.4%, and 92.8% of values fell in zone A, 6.1% fell in zone B, and 1.2% fell in zone C of the surveillance error grid. Median time in range was 78%, with minimum (<1%) time spent in hypoglycemia. StatStrip glucose meter MARD compared with ABL was 5.8%. CONCLUSIONS: Our study shows clinically applicable accuracy and reliability of Dexcom G6 CGM in postoperative ICU patients and a feasible alternative sensor placement site
Accuracy and Feasibility of Real-time Continuous Glucose Monitoring in Critically Ill Patients after Abdominal Surgery and Solid Organ Transplantation
Objectives: Glycemia management in critical care is posing a challenge in frequent measuring and adequate insulin dose adjustment. In recent years continuous glucose measurement is gaining accuracy and reliability in outpatient and inpatient setting. The aim of this study was to assess the feasibility and accuracy of real-time continuous glucose monitoring in ICU patients after major abdominal surgery. Research design and methods: We included patients undergoing pancreatic surgery and solid organ transplantation (liver, pancreas, islets of Langerhans, kidney) requiring ICU stay after surgery. We used a Dexcom G6 sensor, placed in the infraclavicular region, for rtCGM. Arterial blood glucose measured by the amperometric principle (ABL 800, Radiometer, Copenhagen, Denmark) served as reference values and for calibration. Blood glucose was also routinely monitored by StatStrip bedside glucose meter. Sensor accuracy was assessed by mean absolute relative difference (MARD), bias, modified Bland-Altman plot and Surveillance Error Grid for paired samples of glucose values from CGM and ABL. Results: We analyzed data from 61 patients and obtained 1546 paired glucose values from CGM and ABL. Active sensor use was 95.1%. MARD was 9.4%, relative bias 1,4%, 92.8% values fell in zone A, 6.1% in zone B and 1.2% in zone C of Surveillance Error Grid. Median time in range was 78%, with minimum (Conclusions: Our study shows clinically applicable accuracy and reliability of Dexcom G6 CGM in postoperative ICU patients and a feasible alternative sensor placement site.</p